BioRegenx, Inc. is a U.S.-based developer and distributor of medical test equipment, wellness devices, and science-based nutritional products. The company traces its current form to a series of mergers and acquisitions, including the March 2024 merger that gave the business its current name. Its products are sold nationally through a direct selling channel and are aimed at health professionals, research organizations, and wellness-oriented customers. Recent filings indicate the company is still in a development and turnaround phase, with management focused on rebuilding sales, resolving product issues, and securing additional capital to support operations.
−63,0 %
81,1 %
−83,2 %
−20,8 %
0.06
0.04
| % | |
|---|---|
| Medical test equipment | 45% Diagnostic and testing devices developed and manufactured for health-related use. |
| Nutritional products | 35% Science-based supplements and nutritional offerings sold through the company's network. |
| Wellness devices | 15% Consumer and practitioner wellness devices distributed nationally. |
| Distribution and direct selling | 5% Direct-selling channel and related sales support used to reach end customers and professionals. |
BioRegenx sells through a direct-selling model, so its customer base includes end consumers purchasing wellness and...
Buy medical test equipment and related wellness products for professional use and patient-facing recommendations.
Purchase testing equipment and science-based products for research or evaluation purposes.
Buy nutritional products and wellness devices through the company's national direct-selling channel.
Support product reach and repeat sales; their engagement is important to the company's sales recovery.
The company states that its products are sold nationally in the United States, and the available filings do not...
Management's near-term focus is on stabilizing the business after the 2024 merger and rebuilding sales momentum...
Recent sales declines were linked to product issues with the medical testing machine and their spillover effect on nutritional sales.
The company states it will require more capital to fund operations and working capital and may use debt, equity, or strategic arrangements.
The company expects the combination of production activities and the marketing network to create synergies across the group.
BioRegenx faces going-concern and financing risk because management says it will likely continue to generate losses and...
Management states it expects losses and needs additional debt or equity capital, with no assurance funding will be obtained.
The company explicitly linked lower net sales to product issues with the medical testing machine and the effect on nutritional sales.
A concentrated distribution model can amplify the impact of distributor attrition or weak recruitment.
Medical test equipment and wellness products can face compliance, labeling, and safety scrutiny.
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
BIOE · Pharmaceutical Preparations
Bio Essence Corp is a California-based holding company whose operating history has centered on health supplements and OEM manufacturing/distribution services.
BMRA · In Vitro & In Vivo Diagnostic Substances
Pharmaceutical Preparations
Pharmaceutical Preparations
BICX · Services-Specialty Outpatient Facilities, NEC
: 11/08/2026